Eton Pharmaceuticals, Inc. announced that it has appointed Ingrid Hoos as the company’s new Senior Vice President of Scientific Affairs. In the new role, Ms. Hoos will support the company’s regulatory, product development, and quality activities. Ms. Hoos joins Eton after spending nine years as Vice President of Regulatory Affairs at Horizon Therapeutics. At Horizon, Ms. Hoos was responsible for the company’s regulatory strategy and regulatory operations. During her tenure, Horizon’s portfolio grew from one FDA-approved product to ten FDA-approved products. Prior to Horizon Therapeutics, Ingrid held leadership roles in regulatory, quality, and product development at Baxter Healthcare, Takeda Pharmaceuticals, and G.D. Searle (now Pfizer).